Menu

Recent Interviews

Justin Reid, President and CEO, Troilus Gold Corp.

Justin Reid
President and CEO | Troilus Gold Corp.
36 Lombard Street, Floor 4, M5C 2X3 Toronto, Ontario (CAN)

info@troilusgold.com

+1 (647) 276-0050

Interview Troilus Gold: "We are convinced that Troilus is more than just a mine".


John Jeffrey, CEO, Saturn Oil + Gas Inc.

John Jeffrey
CEO | Saturn Oil + Gas Inc.
Suite 1000 - 207 9 Ave SW, T2P 1K3 Calgary (CAN)

info@saturnoil.com

+1-587-392-7900

Saturn Oil + Gas CEO John Jeffrey: "Acquisition has increased production by 2,000%"


Gary Cope, President and CEO, Barsele Minerals

Gary Cope
President and CEO | Barsele Minerals
Suite 1130 - 1055 W. Hastings Street, V6E 2E9 Vancouver (CAN)

info@barseleminerals.com

+1(604) 687-8566

Interview Barsele Minerals: 'I have never seen a project with such good general conditions'.


08. July 2021 | 13:18 CET

BioNTech, Defence Therapeutics, Moderna - The wheel keeps turning

  • Biotechnology
Photo credits: pixabay.com

After a hesitant start, Germany is making good progress with vaccinations. Around 47.5 million people, or 57.1% of the total population, have been vaccinated at least once. The number of fully vaccinated people rises to 39.9%. Rosy prospects for the summer in the republic. But now comes the Delta variant. According to initial studies, it is more resistant to the vaccines currently on the market than other variants. Research is continuing, and new manufacturers are entering the market to participate in the billion-dollar business.

time to read: 3 minutes by Stefan Feulner
ISIN: BIONTECH SE SPON. ADRS 1 | US09075V1026 , DEFENCE THERAPEUTICS INC | CA24463V1013 , MODERNA INC. DL-_0001 | US60770K1079


 

Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author


BioNTech - Efficiency unclear

So far, BioNTech has been spared any bad news regarding its vaccine. However, doubts about the efficacy against the Delta variant are now coming from Israel of all places - the model country for vaccinations. According to initial study results from the renowned Hebrew University in Jerusalem, the BioNTech substance is not as effective against the Delta variant of the virus as had been assumed. The vaccine only prevents 64% of new infections. In February, when Delta was not yet so widespread, the Israeli Ministry of Health had still spoken of a rate of 95.8%. However, the vaccine continues to offer excellent protection against severe illness and hospitalization. Here the result is 93%.

So far, 5.7 million of Israel's 9.3 million inhabitants have been vaccinated for the first time, and 5.2 million have been fully vaccinated. Due to the successes, almost all Corona rules have been lifted by the Israeli government. However, for about 14 days, new Corona infections have increased significantly again, with the Delta variant forming the lion's share despite the high vaccination rate. Due to the negative study results, BioNTech's share price corrected from its high in June of USD 252.58 to USD 206.18. Important support is now the mark at around USD 200.

Defence Therapeutics - Highest efficacy at Delta

Canadian biotechnology Company Defence Therapeutics is taking a new approach with a novel method for fighting cancer and developing vaccines against infectious diseases. The focus is on ACCUM technology, which enables the precise transport of vaccine antigens or antibody-drug conjugates in an intact form to the target cells. This is expected to improve efficiency and efficacy against serious diseases like cancer and infectious diseases such as COVID-19. The ACCUM method of accurately delivering ADCs into cells has increased cell penetration by a factor of 10 compared to other approved ADC solutions.

Now, a first milestone has been reported for the AccuVAC-PT001 vaccine developed by Defence Therapeutics. For example, Sera isolated from animals vaccinated with AccuVAC-PT001 showed a cross-reaction with the spike protein of several SARS-CoV-2 variants. Here, the antibodies produced bind the receptor-binding domains responsible for binding with ACE2 receptors in human cells. Most importantly, the induced antibody response showed cross-reactivity to all SARS-COV-2 variants tested. The highest level of efficacy was observed with the Indian Delta variant.

Additional laboratory studies are currently underway to evaluate the neutralizing ability of the generated antibodies against all strain variants. In addition, the Canadians are continuing both the preclinical and clinical COVID programs. They are working on a second-generation booster vaccine formulation capable of stopping both virus transmission and immune evasion. ACCUM technology has enormous potential and can be used as a base in diverse diseases. However, one thing to keep in mind is that the biotech company still has to work its way through the various stages. However, the announcement in research against the different variants of the SARS-COV-2 virus is an outstanding milestone. With a stock market value of EUR 167 million, Defence Therapeutics is not too expensive at the current research stage.

Moderna - Protected from mutation

The US pharmaceutical Company Moderna recently published data showing that the vaccine protects almost as well against the Delta variant as it does against the original virus after two vaccinations. Studies with blood from vaccinated individuals would have confirmed the protection also for the Delta variant. Based on the positive data, the Moderna vaccine has now been fast-tracked for approval in India. Currently, just over 4% of the population in the country has been vaccinated. The positive news regarding efficacy helped Moderna's shares to jump to a new all-time high. However, experts warn that the Company, which has a market capitalization of USD 87.5 billion, is overvalued.


Shares of vaccine manufacturers have multiplied in recent years and are running into overvaluation. The potential for setbacks is enormous, as seen in the case of CureVac. More interesting here are companies like Defence Therapeutics, which are driving second-generation vaccine development. However, one must not ignore the risk in the biotechnology sector.


Author

Stefan Feulner

The native Franconian has more than 20 years of stock exchange experience and a broadly diversified network.
He is passionate about analyzing a wide variety of business models and investigating new trends.

About the author



Conflict of interest & risk note

In accordance with §34b WpHG we would like to point out that Apaton Finance GmbH as well as partners, authors or employees of Apaton Finance GmbH may hold long or short positions in the aforementioned companies and that there may therefore be a conflict of interest. Apaton Finance GmbH may have a paid contractual relationship with the company, which is reported on in the context of the Apaton Finance GmbH Internet offer as well as in the social media, on partner sites or in e-mail messages. Further details can be found in our Conflict of Interest & Risk Disclosure.


Related comments:

27. July 2021 | 13:01 CET | by Stefan Feulner

BioNTech, XPhyto Therapeutics, MorphoSys - Here we go again

  • Biotechnology

The numbers of new SARS-CoV-2 infections in Germany are rising again, albeit still at a relatively low level. Due to the spread of the Delta variant, Health Minister Jens Spahn warns of incidences beyond the 800 mark as early as this fall. In addition to masking and spacing, the issues surrounding vaccines against the various mutations and regular, reliable testing are returning to the front pages of the news pages.

Read

26. July 2021 | 13:55 CET | by Carsten Mainitz

BioNTech, Cardiol Therapeutics, CureVac - What is next?

  • Biotechnology

Are you smiling or shaking your head? Both are easily understandable reactions that investors might have in light of the latest statements from the Deutsches Aktien Institut (DAI). The DAI calls for better conditions for IPOs of growth companies to prevent such companies from migrating to foreign stock exchanges, as happened with BioNTech, among others. "Especially companies with specialized business models and high financing needs are dependent on foreign investors," explained Uta-Bettina von Altenbockum. However, this is not a new phenomenon either. Other countries have been creating better framework conditions for corporations and better tax incentives for investors for a long time. Own goal. What opportunities are there?

Read

23. July 2021 | 11:37 CET | by André Will-Laudien

CureVac, XPhyto Therapeutics, BioNTech, NanoRepro - Continuous testing or vaccination or both?

  • Biotechnology

Public confusion reigns. The pandemic seems to be locked in chains over the summer, and the population is happy about initial relief with incidences below 10. But now, the first vacationers are already coming back, partly from risk or mutation areas and have to go for testing again as vaccinated persons. It is often forgotten that even those who have been fully vaccinated can be carriers of the virus and can also fall ill, so it should be clear to everyone that personal protective measures must continue to be kept high. Our life with the COVID virus will last much longer than many want to believe...

Read